Francis P. Worden

21.9k total citations · 4 hit papers
257 papers, 9.1k citations indexed

About

Francis P. Worden is a scholar working on Otorhinolaryngology, Oncology and Surgery. According to data from OpenAlex, Francis P. Worden has authored 257 papers receiving a total of 9.1k indexed citations (citations by other indexed papers that have themselves been cited), including 117 papers in Otorhinolaryngology, 115 papers in Oncology and 96 papers in Surgery. Recurrent topics in Francis P. Worden's work include Head and Neck Cancer Studies (117 papers), Lung Cancer Treatments and Mutations (47 papers) and Thyroid Cancer Diagnosis and Treatment (42 papers). Francis P. Worden is often cited by papers focused on Head and Neck Cancer Studies (117 papers), Lung Cancer Treatments and Mutations (47 papers) and Thyroid Cancer Diagnosis and Treatment (42 papers). Francis P. Worden collaborates with scholars based in United States, France and United Kingdom. Francis P. Worden's co-authors include Avraham Eisbruch, Carol R. Bradford, Gregory T. Wolf, Douglas B. Chepeha, Mark E. Prince, Thomas E. Carey, Susan G. Urba, Theodoros N. Teknos, Jeremy M. G. Taylor and Gary D. Hammer and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Francis P. Worden

241 papers receiving 8.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study

2017 497 citations Joshua Bauml, Tanguy Y. Seiwert et al. Journal of Clinical Oncology profile →
Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study

2008 494 citations Ezra E.W. Cohen, Lee S. Rosen et al. Journal of Clinical Oncology profile →
EGFR, p16, HPV Titer, Bcl-xL and p53, Sex, and Smoking As Indicators of Response to Therapy and Survival in Oropharyngeal Cancer

2008 493 citations Bhavna Kumar, Kitrina G. Cordell et al. Journal of Clinical Oncology profile →
Pembrolizumab plus cetuximab in patients with recurrent or metastatic head and neck squamous cell carcinoma: an open-label, multi-arm, non-randomised, multicentre, phase 2 trial

2021 174 citations Francis P. Worden, Douglas R. Adkins et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Francis P. Worden United States	49	3.5k	3.5k	3.1k	2.3k	1.7k	257	9.1k
Erich M. Sturgis United States	56	4.9k 1.4×	4.0k 1.1×	3.2k 1.0×	2.5k 1.1×	3.1k 1.8×	305	11.1k
Lars Bastholt Denmark	42	1.1k 0.3×	4.2k 1.2×	1.3k 0.4×	1.7k 0.7×	1.8k 1.0×	183	8.3k
William H. Westra United States	66	1.6k 0.5×	4.8k 1.4×	3.7k 1.2×	2.3k 1.0×	5.0k 2.9×	208	12.6k
Julie E. Bauman United States	36	1.8k 0.5×	2.7k 0.8×	1.2k 0.4×	1.6k 0.7×	2.6k 1.5×	140	6.6k
Eric Winquist Canada	49	1.3k 0.4×	4.2k 1.2×	3.5k 1.1×	3.1k 1.4×	2.1k 1.2×	291	9.3k
A. Dimitrios Colevas United States	51	2.6k 0.7×	3.4k 1.0×	2.2k 0.7×	2.1k 0.9×	1.6k 0.9×	197	7.6k
K. Kian Ang United States	43	4.9k 1.4×	3.1k 0.9×	3.3k 1.1×	3.1k 1.4×	2.0k 1.2×	75	9.0k
Vivian Weinberg United States	45	1.2k 0.3×	2.2k 0.6×	2.1k 0.7×	3.4k 1.5×	895 0.5×	173	7.8k
George Fountzilas Greece	54	1.3k 0.4×	7.7k 2.2×	2.3k 0.7×	3.7k 1.6×	3.1k 1.8×	576	12.8k
Athanassios Argiris United States	47	3.5k 1.0×	4.2k 1.2×	2.2k 0.7×	2.8k 1.2×	2.7k 1.6×	243	8.9k

Countries citing papers authored by Francis P. Worden

Since Specialization

Citations

This map shows the geographic impact of Francis P. Worden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Francis P. Worden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Francis P. Worden more than expected).

Fields of papers citing papers by Francis P. Worden

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Francis P. Worden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Francis P. Worden. The network helps show where Francis P. Worden may publish in the future.

Co-authorship network of co-authors of Francis P. Worden

This figure shows the co-authorship network connecting the top 25 collaborators of Francis P. Worden. A scholar is included among the top collaborators of Francis P. Worden based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Francis P. Worden. Francis P. Worden is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Leboulleux, Sophie, Laura Boucai, Naifa L. Busaidy, et al.. (2025). Redifferentiation therapy in unresectable or metastatic radioactive iodine refractory thyroid cancer: an International Thyroid Oncology Group statement. The Lancet Diabetes & Endocrinology. 13(6). 516–527. 1 indexed citations

Benjamin, William J., Allen L. Feng, Molly E. Heft Neal, et al.. (2024). Utility of bioselection with neoadjuvant chemotherapy for organ preservation in patients with T4 laryngeal cancer. Oral Oncology. 156. 106917–106917.

Brose, Marcia S., Jaume Capdevila, Rossella Elisei, et al.. (2024). Vandetanib in locally advanced or metastatic differentiated thyroid cancer refractory to radioiodine therapy. Endocrine Related Cancer. 31(8). 4 indexed citations

Dalal, Prarthana, Sarah M. Dermody, Collin Brummel, et al.. (2024). Clinical outcomes in salivary adenoid cystic carcinoma.. Journal of Clinical Oncology. 42(16_suppl). 6102–6102.

Pearson, Alexander T., Kedar Kirtane, Emily L. Bellile, et al.. (2024). Phase I/II Study of A Novel MDM-2 Inhibitor (APG-115-Alrizomadlin) in p53 Wild Type Salivary Gland Cancers. International Journal of Radiation Oncology*Biology*Physics. 118(5). e6–e7. 2 indexed citations

Elner, Victor M., et al.. (2024). Long-Term Outcomes of Neoadjuvant Intraarterial Chemotherapy for Locally Invasive Lacrimal Gland Carcinoma ex Pleomorphic Adenoma. Ophthalmic Plastic and Reconstructive Surgery. 41(4). 432–438.

Haring, Catherine T., Sarah M. Dermody, Collin Brummel, et al.. (2023). Patterns of recurrence in head and neck squamous cell carcinoma to inform personalized surveillance protocols. Cancer. 129(18). 2817–2827. 32 indexed citations

Mayo, Charles S., Michelle Mierzwa, Pratyusha Yalamanchi, et al.. (2023). Machine Learning Model of Emergency Department Use for Patients Undergoing Treatment for Head and Neck Cancer Using Comprehensive Multifactor Electronic Health Records. JCO Clinical Cancer Informatics. 7(7). e2200037–e2200037. 7 indexed citations

Brose, Marcia S., Johannes W. A. Smit, Chia‐Chi Lin, et al.. (2022). Multikinase Inhibitors for the Treatment of Asymptomatic Radioactive Iodine-Refractory Differentiated Thyroid Cancer: Global Noninterventional Study (RIFTOS MKI). Thyroid. 32(9). 1059–1068. 13 indexed citations

10.

Kahana, Alon, Chris Andrews, May P. Chan, et al.. (2021). Vismodegib for Preservation of Visual Function in Patients with Advanced Periocular Basal Cell Carcinoma: The VISORB Trial. The Oncologist. 26(7). e1240–e1249. 21 indexed citations

11.

Papaleontiou, Maria, Nazanene H. Esfandiari, David Reyes‐Gastelum, et al.. (2020). Patient Report of Recurrent and Persistent Thyroid Cancer. Thyroid. 30(9). 1297–1305. 12 indexed citations

12.

Seiwert, Tanguy Y., Sara Kochanny, Kevin Wood, et al.. (2020). A randomized phase 2 study of temsirolimus and cetuximab versus temsirolimus alone in recurrent/metastatic, cetuximab‐resistant head and neck cancer: The MAESTRO study. Cancer. 126(14). 3237–3243. 15 indexed citations

13.

Brose, Marcia S., Francis P. Worden, Kate Newbold, Matthew Guo, & Arti Hurria. (2017). Effect of Age on the Efficacy and Safety of Lenvatinib in Radioiodine-Refractory Differentiated Thyroid Cancer in the Phase III SELECT Trial. Journal of Clinical Oncology. 35(23). 2692–2699. 135 indexed citations

14.

Bauml, Joshua, Tanguy Y. Seiwert, David G. Pfister, et al.. (2017). Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study. Journal of Clinical Oncology. 35(14). 1542–1549. 497 indexed citations breakdown →

15.

Walline, Heather M., Christine M. Komarck, Jonathan B. McHugh, et al.. (2016). Genomic Integration of High-Risk HPV Alters Gene Expression in Oropharyngeal Squamous Cell Carcinoma. Molecular Cancer Research. 14(10). 941–952. 41 indexed citations

16.

Haddad, Robert I., Tanguy Y. Seiwert, David G. Pfister, et al.. (2016). Pembrolizumab after progression on platinum and cetuximab in head and neck squamous cell carcinoma (HNSCC): results from KEYNOTE-055. Annals of Oncology. 27. vi330–vi330. 11 indexed citations

17.

Kahana, Alon, Francis P. Worden, & Victor M. Elner. (2013). Vismodegib as Eye-Sparing Adjuvant Treatment for Orbital Basal Cell Carcinoma. JAMA Ophthalmology. 131(10). 1364–1364. 38 indexed citations

18.

Feng, Felix Y., Hyungjin Myra Kim, Teresa Lyden, et al.. (2010). Intensity-Modulated Chemoradiotherapy Aiming to Reduce Dysphagia in Patients With Oropharyngeal Cancer: Clinical and Functional Results. Journal of Clinical Oncology. 28(16). 2732–2738. 261 indexed citations

19.

Maxwell, Jessica H., Bhavna Kumar, Felix Y. Feng, et al.. (2009). HPV‐positive/p16‐positive/EBV‐negative nasopharyngeal carcinoma in white North Americans. Head & Neck. 32(5). 562–567. 94 indexed citations

20.

Cohen, Ezra E.W., Lee S. Rosen, Everett E. Vokes, et al.. (2008). Axitinib Is an Active Treatment for All Histologic Subtypes of Advanced Thyroid Cancer: Results From a Phase II Study. Journal of Clinical Oncology. 26(29). 4708–4713. 494 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact